<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01347424</url>
  </required_header>
  <id_info>
    <org_study_id>XIANSHENG</org_study_id>
    <nct_id>NCT01347424</nct_id>
  </id_info>
  <brief_title>Evaluating Endostatin Plus TC Regimen in Secondary Malignant Neoplasm of Liver Using Contrast Enhancement Ultrasonography</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Contrast enhancement ultrasonography（CEUS）could be used to evaluate the blood flow perfusion
      liver cancer. In this clinical trial, CEUS was used to evaluated the changes of blood flow
      perfusion of Secondary Malignant Neoplasm of Liver after treated with endostatin plus
      paclitaxel and carboplatin regimen.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The changes of blood flow perfusion in secondary malignant neoplasm of liver</measure>
    <time_frame>12months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparing the difference of OS(Overall Survival) and ORR(Objective Response Rate) according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria in the two different arms.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events in the two different arms</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Nasopharyngeal Cancer</condition>
  <condition>Liver Metastasis</condition>
  <arm_group>
    <arm_group_label>Test group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel , carboplatin, endostatin</intervention_name>
    <description>PTX：175mg/m2，D1, q3w CBP：AUC5，D1, q3w endostatin：7.5 mg/m2 iv 3－4h， d1～15，q3w</description>
    <arm_group_label>Test group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel and Carboplatin</intervention_name>
    <description>PTX：175mg/m2，D1, q3w CBP：AUC5，D1, q3w</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic diagnosis of nasopharyngeal carcinoma or NSCLC

          -  With an evaluable secondary malignant neoplasm of Liver, diameter≥2cm

          -  Without transcatheter arterial chemoembolization (TACE) treatment

          -  Performance status of 0 to 1 on the Eastern Cooperative Oncology Group (ECOG) Scale.

          -  Estimated life expectancy of at least 3 months

          -  Patient compliance and geographic proximity that allow adequate follow-up.

          -  Adequate organ function including the following: Bone marrow: absolute neutrophil
             count (ANC) &gt;or= 1.5x10^9/L, platelets &gt;or= 100x10^9/L, hemoglobin &gt;or= 9g/dL.
             Hepatic: bilirubin &lt;1.5 x ULN, alkaline phosphatase, aspartate transaminase (AST) and
             alanine transaminase (ALT) &lt; 2.5 x ULN (alkaline phosphatase, AST, ALT &lt; 5 x ULN is
             acceptable if liver has tumor involvement). Renal: calculated creatinine clearance &gt;
             45 ml/min.

          -  Men or women of at least 18 years of age.

          -  Signed informed consent from patient.

        Exclusion Criteria:

          -  Women who are pregnant or in lactation

          -  Systemic treatment for another cancer within the year prior to study entry

          -  Known hypersensitivity to any of the study drugs or to drugs with similar chemical
             structures

          -  Use of investigational agents within 28 days of the Baseline visit, or participating
             simultaneously in any other clinical studies

          -  Severe co-morbidity of any type that may interfere with assessment of the patient for
             the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Center of Sun Yat-Sen University (CCSU)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SunYat-senU</name>
      <address>
        <city>GuangZhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2011</study_first_submitted>
  <study_first_submitted_qc>May 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2011</study_first_posted>
  <last_update_submitted>December 5, 2013</last_update_submitted>
  <last_update_submitted_qc>December 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Li Zhang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>NPC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Endostatins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

